Loading organizations...
§ Venture Capital · Oxford, Oxfordshire, United Kingdom
AI-driven pharmaceutical company automating drug design and discovery for pharmaceutical and biotech sectors, focused on precision medicine.
Exscientia is a pharmaceutical company based in the United Kingdom that utilizes artificial intelligence and machine learning to automate drug design and discovery. The firm's computational platform, Centaur Chemist, combines AI with experimental validation to reduce traditional drug discovery timelines from approximately five years to one year while cutting development costs by more than 30 percent. Operating globally with a workforce of approximately 450 scientists and technology experts, the enterprise successfully went public on the NASDAQ exchange in October 2021. The business generates revenue through strategic partnerships and collaborations with major industry players such as Sanofi, GSK, and Evotec, which previously provided a €15 million strategic investment. Featuring notable pharmaceutical industry veterans like Viagra co-inventor Andy Bell on its team, the company was founded as a spinout from the University of Dundee in 2012 by Andrew Hopkins.
Exscientia has raised $432.8M across 6 funding rounds.
Key people at Exscientia.
Exscientia was founded in 2012 by Andrew Hopkins (Co-Founder and CEO).
Exscientia has raised $432.8M in total across 6 funding rounds.
Exscientia has raised $432.8M across 6 funding rounds. Most recently, it raised $225.0M Series D in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 27, 2021 | $225M Series D | SoftBank Vision Fund 2 | BlackRock, Bristol Myers Squibb, Casdin Capital, Andrew Hopkins, Farallon Capital Management, GT Healthcare Capital Partners, Hongkou, Laurion Capital Management, Marshall Wace, Novo Holdings, Pivotal BioVenture Partners | Announced |
| Mar 4, 2021 | $100M Series C | — | William Abecassis, Bristol Myers Squibb, Evotec, GT Healthcare Capital Partners, Novo Holdings | Announced |
| Jan 15, 2021 | $4.2M Grant | Bill & Melinda Gates Foundation | — | Announced |
| May 26, 2020 | $60M Series C | Robert Ghenchev | Bristol Myers Squibb, Evotec, GT Healthcare Capital Partners | Announced |
| Jan 7, 2019 | $26M Series B | — | Celgene, Evotec, GT Healthcare Capital Partners | Announced |
| Sep 28, 2017 | $17.6M Venture Round | Werner Lanthaler | — | Announced |
Key people at Exscientia.
Exscientia was founded in 2012 by Andrew Hopkins (Co-Founder and CEO).
Exscientia has raised $432.8M in total across 6 funding rounds.
Exscientia's investors include SoftBank Vision Fund 2, BlackRock, Bristol Myers Squibb, Casdin Capital, Andrew Hopkins, Farallon Capital Management, GT Healthcare Capital Partners, Hongkou, Laurion Capital Management, Marshall Wace, Novo Holdings, Pivotal bioVenture Partners.